Protara Therapeutics, Inc. announced its financial results for the second quarter ended June 30, 2025, on August 11, 2025. The company reported a net loss of $15 million, or 35 cents per share, for the quarter. Research and development expenses increased by $4.4 million to $10.8 million for the three months ended June 30, 2025, compared to the same period in 2024, driven by clinical trial activities.
General and administrative expenses also rose by $1.5 million to $5.8 million for the three months ended June 30, 2025, reflecting investments in market development and personnel. For the six months ended June 30, 2025, R&D expenses increased by $5.8 million to $19.9 million, and G&A expenses increased by $2.4 million to $10.8 million.
As of June 30, 2025, Protara held approximately $145.6 million in unrestricted cash, cash equivalents, and marketable debt securities, providing an estimated operational runway into mid-2027. The company expects to present interim results from the ADVANCED-2 trial in NMIBC in Q1 2026, dose the first patient in the THRIVE-3 registrational trial of IV Choline Chloride by the end of Q3 2025, and provide an interim update from the STARBORN-1 trial in pediatric LMs in Q4 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.